Antitumor Activity of Lenvatinib (E7080): An Angiogenesis Inhibitor That Targets Multiple Receptor Tyrosine Kinases in Preclinical Human Thyroid Cancer Models
Top Cited Papers
Open Access
- 10 September 2014
- journal article
- Published by Hindawi Limited in Journal of Thyroid Research
- Vol. 2014, 1-13
- https://doi.org/10.1155/2014/638747
Abstract
Inhibition of tumor angiogenesis by blockading the vascular endothelial growth factor (VEGF) signaling pathway is a promising therapeutic strategy for thyroid cancer. Lenvatinib mesilate (lenvatinib) is a potent inhibitor of VEGF receptors (VEGFR1–3) and other prooncogenic and prooncogenic receptor tyrosine kinases, including fibroblast growth factor receptors (FGFR1–4), platelet derived growth factor receptorα(PDGFRα), KIT, and RET. We examined the antitumor activity of lenvatinib against human thyroid cancer xenograft models in nude mice. Orally administered lenvatinib showed significant antitumor activity in 5 differentiated thyroid cancer (DTC), 5 anaplastic thyroid cancer (ATC), and 1 medullary thyroid cancer (MTC) xenograft models. Lenvatinib also showed antiangiogenesis activity against 5 DTC and 5 ATC xenografts, while lenvatinib showed in vitro antiproliferative activity against only 2 of 11 thyroid cancer cell lines: that is, RO82-W-1 and TT cells. Western blot analysis showed that cultured RO82-W-1 cells overexpressed FGFR1 and that lenvatinib inhibited the phosphorylation of FGFR1 and its downstream effector FRS2. Lenvatinib also inhibited the phosphorylation of RET with the activated mutation C634W in TT cells. These data demonstrate that lenvatinib provides antitumor activity mainly via angiogenesis inhibition but also inhibits FGFR and RET signaling pathway in preclinical human thyroid cancer models.Keywords
This publication has 49 references indexed in Scilit:
- New Insight into the Treatment of Advanced Differentiated Thyroid CancerJournal of Thyroid Research, 2012
- New Molecular Targeted Therapy and Redifferentiation Therapy for Radioiodine-Refractory Advanced Papillary Thyroid Carcinoma: Literature ReviewJournal of Thyroid Research, 2012
- A phase I study of E7080, a multitargeted tyrosine kinase inhibitor, in patients with advanced solid tumoursBritish Journal of Cancer, 2012
- Differentiated Thyroid Cancer: Management of Patients with Radioiodine Nonresponsive DiseaseJournal of Thyroid Research, 2012
- Vandetanib in Patients With Locally Advanced or Metastatic Medullary Thyroid Cancer: A Randomized, Double-Blind Phase III TrialJournal of Clinical Oncology, 2012
- Treatment Outcome of Patients with Anaplastic Thyroid Cancer: A Single Center ExperienceYonsei Medical Journal, 2012
- The role of the PAX8/PPARγ fusion oncogene in the pathogenesis of follicular thyroid cancerMolecular and Cellular Endocrinology, 2010
- Anaplastic thyroid cancer: molecular pathogenesis and emerging therapiesEndocrine-Related Cancer, 2009
- Patterns and Emerging Mechanisms of the Angiogenic Switch during TumorigenesisCell, 1996
- Induction of angiogenesis during the transition from hyperplasia to neoplasiaNature, 1989